Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 172

Sort by

Sort Order Select

Journal Articles

Venetoclax Synergizes with the RNA-Directed Nucleoside Analog 8-Chloro-Adenosine in Acute Myeloid Leukemia in Vitro and In Vivo

Ralf Buettner, PhD, Le Xuan Truong Nguyen, PhD, Corey James Morales, BA, BS, Lisa S Chen, PhD, Timothy Synold, PhD, Dinh Hoa Hoang, BS, Bin Amber Zhang, PhD, Lucy Ghoda, PhD, Varsha Gandhi, PhD, Vinod A. Pullarkat, MD, Guido Marcucci, MD, Steven T. Rosen, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-143240

Published: 2020

Journal Articles

Repurposing Nelarabine to Induce Differentiation of Acute Myeloid Leukemia

Hanying Wang, Xin He, MD, Feiteng Huang, MS, Haojie Dong, PhD, Wei Chen, PhD, Zheng Li, MS, Jie Sun, PhD, Yinghui Zhu, PhD, Lei Zhang, MD, Yuhui Wu, MD, Lifeng Feng, PhD, Jing Zhang, PhD, Samer Khaled, MD, Guido Marcucci, MD, David Sykes, MD PhD, Hongchuan Jin, MD PhD, Xian Wang, MD PhD, Ling Li, PhD

Blood (2020) 136 (Supplement 1): 26.

https://doi.org/10.1182/blood-2020-139922

Published: 2020

Journal Articles

Hemorrhagic Cystitis in Patients Undergoing Allogeneic Hematopoietic Cell Transplant with Post Transplant Cyclophosphamide As GvHD Prophylaxis

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-139993

Published: 2020

Journal Articles

Superior Therapy Response Predictions for Patients with Myelodysplastic Syndrome (MDS) Using Cellworks Singula™: Mycare-020-02

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-142214

Published: 2020

Journal Articles

Clinical Outcomes of Patients with Secondary Acute Myeloid Leukemia (sAML) Treated with Hypomethylating Agent Plus Venetoclax (HMA-Ven) or Liposomal Daunorubicin Cytarabine (CPX-351)

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-140538

Published: 2020

Journal Articles

Outcomes of Therapy with Venetoclax Combined with Hypomethylating Agents in Favorable-Risk Acute Myeloid Leukemia (AML)

Shukaib Arslan, MD, Jianying Zhang, Prajwal Dhakal, MBBS, Jenna A. Moran, NP, Nuthana Naidoo, Jennifer Lombardi Story, Vinod A. Pullarkat, MD, Anthony S. Stein, MD, Guido Marcucci, MD, George Yaghmour, MD, Vijaya R. Bhatt, MD, Amir T. Fathi, Ibrahim Aldoss, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-142780

Published: 2020

Journal Articles

Assessment of Cellworks Omics Biosimulation Therapy Response Predictions for Patients with Acute Myeloid Leukemia (AML) Using Cellworks Singula™: Mycare-020-01

Blood (2020) 136 (Supplement 1): 35.

https://doi.org/10.1182/blood-2020-142184

Published: 2020

Journal Articles

Microrna-142 Deficiency Promotes Chronic Myeloid Leukemia (CML) Transformation from Chronic Phase (CP) to Blast Crisis (BC)

Bin Amber Zhang, PhD, Dandan Zhao, MD, Huafeng Wang, MD, Chen Liang, MD, Le Xuan Truong Nguyen, PhD, Junjing Qiao, MD PhD, Shanshan Suo, MD, Yasmin Elhajmoussa, Lucy Ghoda, PhD, David Frankhouser, Russell Rockne, PhD, Ling Li, PhD, Ya-Huei Kuo, PhD, Mark Boldin, MD PhD, Guido Marcucci, MD

Blood (2020) 136 (Supplement 1): 4.

https://doi.org/10.1182/blood-2020-143202

Published: 2020

Journal Articles

Activated Natural Killer Cells Are Associated with Poor Clinical Prognosis in High-Risk B- and T- Cell Acute Lymphoblastic Leukemia

Caroline Duault, PharmD, PhD, Anil Kumar, PhD, Adeleh Taghi Khani, PhD, Sung June Lee, BA, Lu Yang, PhD, Min Huang, PhD, Christian Hurtz, PhD, Bryan Manning, BS, Lucy Ghoda, PhD, Tinisha McDonald, BS, Norman J. Lacayo, MD, Kathleen M. Sakamoto, MD PhD, Martin P. Carroll, MD, Guido Marcucci, MD, Jianhua Yu, PhD, Michael A. Caligiuri, MD, Holden T. Maecker, PhD, Srividya Swaminathan, PhD

Blood (2020) 136 (Supplement 1): 39.

https://doi.org/10.1182/blood-2020-140044

Published: 2020

Journal Articles

Total Marrow and Lymphoid Irradiation (TMLI) at a Dose of 2000cGy in Combination with Post-Transplant Cyclophosphamide (PTCy)-Based Graft Versus Host Disease (GvHD) Prophylaxis Is Safe and Associated with Favorable GvHD-Free/Relapse-Free Survival at 1 Year in Patients with Acute Myeloid Leukemia (AML)

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-141469

Published: 2020

Journal Articles

Efficacy of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Peripheral Blood Stem Cell HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation; A Prospective Pilot Trial

Monzr M. Al Malki, MD, Ni-Chun Tsai, MS, Joycelynne Palmer, PhD, Saloomeh Mokhtari, Thai Cao, MD, Haris Ali, MD, Amandeep Salhotra, MD, Shukaib Arslan, MD, Ibrahim Aldoss, MD, Nicole Karras, MD, Haris M. Ali, MD, Haris Ali, MD, Anthony S. Stein, MD, David S Snyder, MD, Guido Marcucci, MD, Stephen J. Forman, MD, Ryotaro Nakamura, MD

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-142807

Published: 2020

Journal Articles

Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma

Ada Dona', PhD, Domenico Viola, Enrico Caserta, PhD, Francesca Besi, PhD, James F Sanchez, PhD, Guido Marcucci, MD, Jonathan J Keats, PhD, Amrita Y. Krishnan, MD, Matt Coffey, PhD, Douglas W. Sborov, MDMSc, Gerard Nuovo, MD, Craig C Hofmeister, MDMPH, Flavia Pichiorri, PhD

Blood (2019) 134 (Supplement_1): 1816.

https://doi.org/10.1182/blood-2019-128740

Published: 2019

Journal Articles

FLT3-ITD Activates Cytoplasmic Drosha-Dependent Non-Canonical Mechanisms of Mir-155 Biogenesis in Acute Myeloid Leukemia

Le Xuan Truong Nguyen, PhD, Bin Zhang, PhD, Dinh Hoa Hoang, BS, Dandan Zhao, MD, Sergio Branciamore, Davide Maestrini, PhD, Yu-Lin SU, PhD, Sonia Rodriguez, PhD, Flavia Pichiorri, PhD, Steven Rosen, MD, Michael A. Caligiuri, MD, Stephen J. Forman, MD, Ling Li, PhD, Marcin Kortylewski, PhD, Russell Rockne, PhD, Ya-Huei Kuo, PhD, Nadia Carlesso, MD, Guido Marcucci, MD

Blood (2019) 134 (Supplement_1): 2722.

https://doi.org/10.1182/blood-2019-131871

Published: 2019

Journal Articles

The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results

David A Sallman, MD, Adam S. Asch, MD, Monzr M. Al Malki, MD, Daniel J. Lee, MD, William B. Donnellan, MD, Guido Marcucci, MD, Suman Kambhampati, MD, Naval G. Daver, MD, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD, Joanna Van Elk, Ming Lin, PhD, Jens-Peter Volkmer, MD, Chris H Takimoto, MD PhD, Mark Chao, MD PhD, Paresh Vyas, MD PhD

Blood (2019) 134 (Supplement_1): 569.

https://doi.org/10.1182/blood-2019-126271

Published: 2019

Journal Articles

HDAC8 Promotes MLL-Rearranged Acute Myeloid Leukemia By Inhibiting p53 Acetylation

Dijiong Wu, MD, Man Li, PhD, Lianjun Zhang, PhD, Jing Qi, PhD, Chun-Wei David Chen, PhD, Xin He, PhD, Yinghui Zhu, PhD, Haojie Dong, PhD, Jie Sun, PhD, Ling Li, PhD, Guido Marcucci, MD, Ya-Huei Kuo, PhD

Blood (2019) 134 (Supplement_1): 642.

https://doi.org/10.1182/blood-2019-124134

Published: 2019

Journal Articles

Effective Novel Fto Inhibitors Show Potent Anti-Cancer Efficacy and Suppress Drug Resistance

Blood (2019) 134 (Supplement_1): 233.

https://doi.org/10.1182/blood-2019-124535

Published: 2019

Journal Articles

A 14q32.31 Genomic-Imprinted DLK1-DIO3 microrna promotes Leukemogenesis By Inducing Stem Cell Quiescence and Inhibiting NK Cell Anti-Cancer Immunity

Blood (2019) 134 (Supplement_1): 4141.

https://doi.org/10.1182/blood-2019-131113

Published: 2019

Journal Articles

Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplantation: Outcome Data Analysis

Janny M. Yao, PharmD, Dongyun Yang, PhD, Saloomeh Mokhtari, Amandeep Salhotra, MD, Haris Ali, MD, Shukaib Arslan, MD, Salman Otoukesh, MD, Ibrahim Aldoss, MD, Karamjeet S. Sandhu, MD, Anthony Stein, MD, David Snyder, MD, Vinod A. Pullarkat, MD, Guido Marcucci, MD, Stephen J Forman, MD, Ryotaro Nakamura, MD, Monzr M. Al Malki, MD

Blood (2019) 134 (Supplement_1): 4518.

https://doi.org/10.1182/blood-2019-129221

Published: 2019

Journal Articles

Spred1 Insufficiency in the Hematopoietic and/or Vascular Compartments of the Bone Marrow (BM) Niche Promotes Aggressive Leukemogenesis in Chronic Myelogenous Leukemia (CML)

Junjing Qiao, MD PhD, Dandan Zhao, MD, Le Xuan Truong Nguyen, PhD, Herman Wu, BS, Gang Liu, PhD, Shanshan Suo, MD, Huafeng Wang, Yasmin Elhajmoussa, Chen Liang, MD, David Snyder, MD, Haris Ali, MD, Steven Rosen, MD, Nadia Carlesso, MD, Ling Li, PhD, Ya-Huei Kuo, PhD, Guido Marcucci, MD, Bin Zhang, PhD

Blood (2019) 134 (Supplement_1): 3791.

https://doi.org/10.1182/blood-2019-127616

Published: 2019

Journal Articles

Anti-MiR-126 Therapy for Inv(16) Acute Myeloid Leukemia

Lianjun Zhang, PhD, Le Xuan Truong Nguyen, PhD, Dijiong Wu, MD, Casey J Brewer, PhD, Xin He, PhD, Man Li, PhD, Dandan Zhao, MD, Guerry Jeanne Cook, PhD, Jing Qi, PhD, Herman Wu, BS, Bin Zhang, PhD, Ling Li, PhD, Marcin Kortylewski, PhD, Guido Marcucci, MD, Ya-Huei Kuo, PhD

Blood (2019) 134 (Supplement_1): 3914.

https://doi.org/10.1182/blood-2019-123468

Published: 2019

NARROW

Venetoclax Synergizes with the RNA-Directed Nucleoside Analog 8-Chloro-Adenosine in Acute Myeloid Leukemia in Vitro and In Vivo

Repurposing Nelarabine to Induce Differentiation of Acute Myeloid Leukemia

Hemorrhagic Cystitis in Patients Undergoing Allogeneic Hematopoietic Cell Transplant with Post Transplant Cyclophosphamide As GvHD Prophylaxis

Superior Therapy Response Predictions for Patients with Myelodysplastic Syndrome (MDS) Using Cellworks Singula™: Mycare-020-02

Clinical Outcomes of Patients with Secondary Acute Myeloid Leukemia (sAML) Treated with Hypomethylating Agent Plus Venetoclax (HMA-Ven) or Liposomal Daunorubicin Cytarabine (CPX-351)

Outcomes of Therapy with Venetoclax Combined with Hypomethylating Agents in Favorable-Risk Acute Myeloid Leukemia (AML)

Assessment of Cellworks Omics Biosimulation Therapy Response Predictions for Patients with Acute Myeloid Leukemia (AML) Using Cellworks Singula™: Mycare-020-01

Microrna-142 Deficiency Promotes Chronic Myeloid Leukemia (CML) Transformation from Chronic Phase (CP) to Blast Crisis (BC)

Activated Natural Killer Cells Are Associated with Poor Clinical Prognosis in High-Risk B- and T- Cell Acute Lymphoblastic Leukemia

Efficacy of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Peripheral Blood Stem Cell HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation; A Prospective Pilot Trial

Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma

FLT3-ITD Activates Cytoplasmic Drosha-Dependent Non-Canonical Mechanisms of Mir-155 Biogenesis in Acute Myeloid Leukemia

The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results

HDAC8 Promotes MLL-Rearranged Acute Myeloid Leukemia By Inhibiting p53 Acetylation

Effective Novel Fto Inhibitors Show Potent Anti-Cancer Efficacy and Suppress Drug Resistance

A 14q32.31 Genomic-Imprinted DLK1-DIO3 microrna promotes Leukemogenesis By Inducing Stem Cell Quiescence and Inhibiting NK Cell Anti-Cancer Immunity

Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplantation: Outcome Data Analysis

Spred1 Insufficiency in the Hematopoietic and/or Vascular Compartments of the Bone Marrow (BM) Niche Promotes Aggressive Leukemogenesis in Chronic Myelogenous Leukemia (CML)

Anti-MiR-126 Therapy for Inv(16) Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only